ALLOPURINOL SODIUM

Post-LOE

allopurinol

ANDAINJECTIONINJECTABLE
Approved
Jan 2022
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
19

Mechanism of Action

base, hypoxanthine. Allopurinol and its oxypurinol metabolite inhibitor xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in humans. Allopurinol does not disrupt the biosynthesis of purines. The…

Clinical Trials (5)

NCT04550234Phase 1Completed

A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol

Started Apr 2021
25 enrolled
Chronic Kidney Disease
NCT04532918Phase 1Completed

Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers

Started Sep 2020
14 enrolled
Chronic Kidney Disease
NCT03990363Phase 2Completed

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

Started Jul 2019
861 enrolled
Chronic Kidney Disease
NCT03836599Phase 1Completed

A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects

Started Jan 2019
6 enrolled
Chronic Kidney Disease
NCT01451645Phase 4Completed

Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol

Started Oct 2011
82 enrolled
Intercritical Gout